Quest Magazine

Buy a MDA Shamrock, Help Conquer Muscle Disease

NIH Will Test Antioxidant Drug in Central Core Disease

The National Institute of Nursing Research (NINR) at the National Institutes of Health in Bethesda, Md., is conducting a study to determine if an antioxidant drug that has been approved by the U.S. Food and Drug Administration for other indications can reduce the severity of some symptoms in people with central core disease (CCD), a genetic disease caused by defects in a structure known as ryanodine receptor 1 (RYR1).

Lowe’s Supports Annual MDA Shamrock Program to Help Build Stronger Futures for Families Fighting Muscle Disease

Drug Development for DMD: February 2015 Update

Development of treatments for Duchenne muscular dystrophy (DMD) continues to advance. Many of the new investigational drugs are potentially applicable to all DMD patients, while a few target those with specific mutations in the dystrophin gene.

Fighting fibrosis

Sailormen Inc. Kicks Off Annual "Appetite for a Cure" Campaign to Help MDA Fuel the Fight for Muscle Health

Genervon's 'Master Regulator' Drug Encourages ALS Community

Biopharmaceutical company Genervon has announced what it considers encouraging  results from a "compassionate use" trial of its experimental drug GM604 in a single patient with advanced  amyotrophic lateral sclerosis (ALS).

MDA Names Kristin Stephenson to VP of Policy and Advocacy to Build on Recent Landmark Victories

DMD: Eteplirsen Data Still Encouraging After Three Years

Boys with Duchenne muscular dystrophy (DMD) caused by specific genetic mutations who were treated with the experimental drug eteplirsen for 168 weeks (3.2 years) continued to show an advantage in the distance they were able to walk compared to those treated with the drug for only 144 weeks (2.8 years), although all boys had declined in walking distance since the start of this phase 2b trial of eteplirsen.

ALS Stem Cell Trials Move Forward

Stem cells -- cells at an early stage of development that can mature and fulfill specific roles depending on their environment and signals they receive – have intrigued scientists as a possible treatment for amyotrophic lateral sclerosis (ALS) for several years. Now, two biotechnology companies – BrainStorm Cell Therapeutics and Neuralstem – are reporting encouraging results from ALS clinical trials.

Wisconsin Girl Returns as MDA National Goodwill Ambassador in 2015

Pages